Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of V-Boost in Refractory GBM
NCT03916757Phase 2Unknown
- Sponsor
- Immunitor Inc.
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of V-Boost in glioblastoma multiforme (GBM), sponsored by Immunitor Inc. Primary endpoint: Effect on tumor size at 3 months. Status: unknown.
02
Drugs
V-Boost
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT03916757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03916757.